KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks.N Engl J MedPMID 38819658无 PMCID2024-Jul-040.98未发现恶性肿瘤人群证据。待处理
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.N Engl J MedPMID 38959480无 PMCID2024-Jul-040.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis.J Bone Joint Surg AmPMID 38691582PMC115940692024-Jul-030.98未发现恶性肿瘤人群证据。待处理
Mean Arterial Pressure and Neonatal Outcomes in Pregnancies Complicated by Mild Chronic Hypertension.Obstet GynecolPMID 38781591PMC112168572024-Jul-010.98未发现恶性肿瘤人群证据。待处理
Pregnancy Outcomes of Nifedipine Compared With Labetalol for Oral Treatment of Mild Chronic Hypertension.Obstet GynecolPMID 38949541PMC112190062024-Jul-010.98未发现恶性肿瘤人群证据。待处理
Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADAR.Int J Radiat Oncol Biol PhysPMID 37802226无 PMCID2024-Jul-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD).Int J Radiat Oncol Biol PhysPMID 38072326无 PMCID2024-Jul-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.HaematologicaPMID 38299578PMC112153832024-Jul-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Secondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable-risk prostate cancer patients receiving docetaxel: Insights from a randomized trial.CancerPMID 38427287无 PMCID2024-Jul-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT).J RheumatolPMID 38621793无 PMCID2024-Jul-010.95The study is not oncology-focused; it investigates rheumatoid arthritis. The primary efficacy outcomes are clinical response criteria (e.g., CDAI remission, DAS28-CRP <2.6, ACR20/50/70), which are not time-to-event endpoints like OS, PFS, DFS, EFS, RFS, or TTP, and there is no indication of Kaplan-Meier analysis or hazard ratios for such an endpoint.待处理
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.J Clin OncolPMID 38648575PMC112109462024-Jul-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).J Nucl MedPMID 38664019PMC112187232024-Jul-010.95The study is an eligible human oncology randomized phase III trial with a primary time-to-event endpoint, but it evaluates a diagnostic imaging intervention (PSMA PET/CT) and lacks a drug-containing intervention, which is a required criterion.待处理
A Prospective Randomized Multicenter Study on the Impact of [18F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer.J Nucl MedPMID 38844361无 PMCID2024-Jul-010.70The study meets criteria for oncology, human subjects, randomized design, Phase III status, and time-to-event endpoints. However, the primary intervention is a diagnostic imaging agent/procedure, not a drug-containing therapeutic intervention. Therefore, it is excluded.待处理
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.Int J Gynecol CancerPMID 38950925PMC112281982024-Jul-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial.JAMA Netw OpenPMID 38980676PMC112342332024-Jul-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers.JNCI Cancer SpectrPMID 39067037PMC113166152024-Jul-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 study.J Geriatr OncolPMID 37211514无 PMCID2024-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma.BJU IntPMID 38009394无 PMCID2024-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of MC-003 solution for endoscopic mucosal or submucosal resection: a prospective, multicenter, randomized, triple-blinded, parallel-group, phase III study.Gastrointest EndoscPMID 38184114无 PMCID2024-Jul0.95Study meets oncology, human, randomized, and phase III criteria with original results, but is excluded because the intervention is a non-drug procedural solution and the endpoints are not time-to-event efficacy outcomes.待处理
Glycemic Trends in Patients with Thyroid Eye Disease Treated with Teprotumumab in 3 Clinical Trials.OphthalmologyPMID 38253291无 PMCID2024-Jul0.98未发现恶性肿瘤人群证据。待处理
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774).Eur UrolPMID 38290964PMC128820652024-Jul0.85The record describes a Phase III randomized trial in human oncology with a primary time-to-event efficacy endpoint (biochemical recurrence-free survival). However, the intervention is a diagnostic imaging modality (PSMA-PET) and not a drug-containing regimen. Therefore, it does not meet the 'drug-containing intervention' criterion for inclusion.待处理
Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3).Am J OphthalmolPMID 38395329无 PMCID2024-Jul0.98未发现恶性肿瘤人群证据。待处理
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.J Allergy Clin ImmunolPMID 38431226无 PMCID2024-Jul0.98未发现恶性肿瘤人群证据。待处理
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial.J Thorac OncolPMID 38460751无 PMCID2024-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa.Mov Disord Clin PractPMID 38465885PMC112338342024-Jul0.98未发现恶性肿瘤人群证据。待处理
Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study).Bone Marrow TransplantPMID 38493275PMC112263932024-Jul0.95This record is for a non-randomized, observational study (ATOS) that compares its results to a previously reported Phase III randomized trial. It is not an original report of the randomized trial's results.待处理
Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.Leuk LymphomaPMID 38501751无 PMCID2024-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial.Clin Breast CancerPMID 38514306无 PMCID2024-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study.Gynecol OncolPMID 38554625无 PMCID2024-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study.J Am Acad DermatolPMID 38554938无 PMCID2024-Jul0.98未发现恶性肿瘤人群证据。待处理
Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma.J Allergy Clin Immunol PractPMID 38555079无 PMCID2024-Jul0.98未发现恶性肿瘤人群证据。待处理
Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials.Osteoporos IntPMID 38573517PMC112111432024-Jul0.98未发现恶性肿瘤人群证据。待处理
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study.Eur UrolPMID 38582713PMC118902012024-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Retagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.Diabetes Obes MetabPMID 38602409无 PMCID2024-Jul0.98未发现恶性肿瘤人群证据。待处理
First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study.EsophagusPMID 38607538PMC111992452024-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
The Influence of Surgical Complexity and Center Experience on Postoperative Morbidity After Minimally Invasive Surgery in Gynecologic Oncology: Lessons Learned from the ROBOGYN-1004 Trial.Ann Surg OncolPMID 38616209PMC111647582024-Jul0.45The metadata confirms an oncology, human, randomized, Phase III trial, but the reported outcome is postoperative morbidity, not a survival or time-to-event efficacy endpoint. Therefore, it is not eligible for the Kaplan-Meier digitization cohort.待处理
Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial.Diabetes Obes MetabPMID 38618970无 PMCID2024-Jul0.98未发现恶性肿瘤人群证据。待处理
A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE).Radiother OncolPMID 38636708无 PMCID2024-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Using the genomic adjusted radiation dose (GARD) to personalize the radiation dose in nasopharyngeal cancer.Radiother OncolPMID 38636709无 PMCID2024-Jul0.90The study is a secondary biomarker analysis (correlating GARD with locoregional control) from a randomized Phase III trial. While it meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result, it does not present a primary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR from the original trial. The deterministic review correctly identified the lack of a time-to-event signal. Therefore, it is not eligible for the oncology Kaplan-Meier digitization cohort.待处理
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years.Contemp Clin TrialsPMID 38636725PMC76181642024-Jul0.98未发现恶性肿瘤人群证据。待处理
Early postnatal high-dose fat-soluble enteral vitamin A supplementation for moderate or severe bronchopulmonary dysplasia or death in extremely low birthweight infants (NeoVitaA): a multicentre, randomised, parallel-group, double-blind, placebo-controlled, investigator-initiated phase 3 trial.Lancet Respir MedPMID 38643780无 PMCID2024-Jul0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial.Lancet Gastroenterol HepatolPMID 38670135无 PMCID2024-Jul0.98未发现恶性肿瘤人群证据。待处理
Placebo response in patients with Dravet syndrome: Post-hoc analysis of two clinical trials.Epilepsy BehavPMID 38677101无 PMCID2024-Jul0.98未发现恶性肿瘤人群证据。待处理
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.Am J Clin DermatolPMID 38698175PMC111936932024-Jul0.95The study is a Phase III randomized trial of ruxolitinib cream for atopic dermatitis, which is a non-oncologic inflammatory skin condition. The efficacy endpoints are categorical or continuous measures (IGA-TS, EASI-75, NRS4) without a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR). Therefore, it does not meet the oncology or time-to-event criteria for inclusion.待处理
Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trials.Diabetes Obes MetabPMID 38698650无 PMCID2024-Jul0.98未发现恶性肿瘤人群证据。待处理
Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Gastroenterol HepatolPMID 38723644无 PMCID2024-Jul0.98未发现恶性肿瘤人群证据。待处理
Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study.Eur J CancerPMID 38749110无 PMCID2024-Jul1.00命中用户提供的消化道肿瘤阳性参考集。待处理
Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I).Eur J Drug Metab PharmacokinetPMID 38750386无 PMCID2024-Jul0.98未发现恶性肿瘤人群证据。待处理
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer.Ann OncolPMID 38755096无 PMCID2024-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies.HIV MedPMID 38760011无 PMCID2024-Jul0.98未发现恶性肿瘤人群证据。待处理